A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. - Wikidata - awgldk - TriplyDB

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

http://www.wikidata.org/entity/Q30493217

about

Advanced techniques using contrast media in neuroimaging Anti-angiogenic therapy for high grade glioma Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Cancer imaging by optical coherence tomography: preclinical progress and clinical potential.Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Biphasic modeling of brain tumor biomechanics and response to radiation treatment Tumor angiogenesis and vascular patterning: a mathematical model Emerging Techniques in Brain Tumor Imaging: What Radiologists Need to Know 3D Slicer as an image computing platform for the Quantitative Imaging Network Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study Perfusion MRI: the five most frequently asked clinical questions.Angiogenic inhibition in high-grade gliomas: past, present and future.Multimodal MR imaging model to predict tumor infiltration in patients with gliomas.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Functional imaging in adult and paediatric brain tumours.Pseudoprogression in high-grade glioma.Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Advanced magnetic resonance imaging of the physical processes in human glioblastoma.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors.ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.Genetics of glioblastoma: a window into its imaging and histopathologic variability.Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response.Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.Perfusion and permeability MR imaging of gliomas.Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

P2860

Q22252349-376819AB-D32E-4278-937B-CBD7420978EE Q24240185-233B6254-B225-4980-86E5-434F9C08D3DC Q24632791-D71FB579-7DB6-4F22-85E7-DE5714C32DEC Q26743358-602CF12F-AA9C-4786-9635-DF9BF77604D2 Q26746067-5D14CF23-A9B6-4786-ACC2-20144F7485D8 Q26799458-DA89557B-A9D1-4CD0-B5A5-646EB69E004D Q26823084-6C25C6C3-ECF5-40CC-8AF1-02AF93CAF265 Q26853308-7CFD17AD-AD99-4550-87F9-D22DCD59B2D7 Q27310114-3641D426-85D1-45BE-BB34-EA5B3D8665DD Q27339985-117451FA-ACEF-4B82-95EC-0E91F48D0E13 Q28068259-8D0174A5-F121-4B0F-B4EA-41EF105CAB1C Q28727260-43A48E55-9C52-4983-9943-8C05716631D5 Q28742242-A5E24AFD-51AF-48BA-BC88-A125C26EB51D Q30300114-0D1F7DC0-48D0-469C-9B54-E0AFD8517BAA Q30399006-40783BE1-9C4A-43AD-9D0C-58CEAD2BD09C Q30413713-3B0F813D-9F95-45FA-A61D-DC31BE76BD90 Q30416198-07D5A110-3DB4-4929-9374-CE491206D20F Q30455596-ED8DD135-7E39-4AA0-871C-E0DBB7786320 Q30457230-BFC4FE05-F72A-406D-B421-CEDB799A746E Q30469815-AB666AE5-3198-46BA-9084-38C4E64FB8CD Q30471456-92E7F3F3-C485-483D-828C-96392CD646C9 Q30525290-EE2F4900-BC45-43AF-9763-EE25780D48D6 Q30542073-BCF75656-0E86-41FA-B12E-65DE1568D7BA Q30577397-0028BE0C-3D24-4544-A023-E05821909809 Q30578798-68643A41-AB63-4A6E-86B5-BF17679E6956 Q30651792-8FEE4335-5B8E-4954-8D98-DA788EFBA02E Q30653828-D456D833-E6BD-403F-82B8-4FAFA5714473 Q30764736-05856248-FA90-40E2-8B83-85875175B9C9 Q30797166-3EEB1DDB-23E7-4BEF-BE33-7BAA99DD56ED Q30847284-E70215CF-ECE4-4EB4-8A8D-E9E20D2D44E4 Q30907831-9BE792EC-E278-4F3F-AF3B-DE3DE0CD72AA Q30930526-4ECAC3B0-1379-4883-A856-DA3AD54C4627 Q30938805-E52407DE-5C3B-4574-9296-60640783FCC6 Q33391770-65390F8B-992F-4B26-8A62-D4A1FA12A8AE Q33562673-9E90C3C9-BC14-4541-BF77-C67DEE3D78BC Q33620506-0E5BBB39-2B26-40B4-92B0-7AA25B803B35 Q33632105-3C9F2818-889F-40A3-92BD-4A8048C84515 Q33733303-2B454920-94D9-435B-8302-419063DFC986 Q33788231-D44216A5-D53C-4272-B9EC-366235935F14 Q33793253-70716173-8CA9-4CF8-8613-6B03AEC64C60

P2860

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

http://www.wikidata.org/entity/Q30493217

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

A "vascular normalization inde ...... current glioblastoma patients.

@ast

A "vascular normalization inde ...... current glioblastoma patients.

@en

type

label

A "vascular normalization inde ...... current glioblastoma patients.

@ast

A "vascular normalization inde ...... current glioblastoma patients.

@en

prefLabel

A "vascular normalization inde ...... current glioblastoma patients.

@ast

A "vascular normalization inde ...... current glioblastoma patients.

@en

P1433

Q30493217-11D7E9B8-107C-46A1-8552-0B878FF5EE80

P1476

Q30493217-420B59AF-1466-4DF7-B145-3F844CE65F27

P2093

Q30493217-05D8D7C3-9239-484A-84DB-40568A21B44F

Q30493217-362EF166-F11D-41F8-8E2E-94DA14F0A6A4

Q30493217-47129EFD-B941-40AE-829E-D330A997F41B

Q30493217-6673B74A-B4B3-4495-AF7B-2039BB406D47

Q30493217-69AB3AC4-809C-463F-9043-ED4E02918F82

Q30493217-6F46DC28-541C-4BBE-A57F-6252F629C2FA

Q30493217-977BAD4D-EB27-4D90-ADD0-7D46C3AFF116

Q30493217-A75EFE8B-DB0D-41B2-A4FB-AA9C12506FE3

Q30493217-A84EDD25-5A71-49E8-B559-572C4D03AF21

Q30493217-C6ADC090-3604-4632-AE24-0EFA78991D12

P2860

Q30493217-0E744D37-27C3-47AD-A022-C962B25816E1

Q30493217-30DDFC6E-C3C4-481F-82A1-145BBFA603FD

Q30493217-3A1305DF-E032-4E22-999E-0452C448C6B3

Q30493217-42D1B8D2-5DD0-46C4-BEF9-4BC22D2FD019

Q30493217-5F5B3301-1174-4D59-86A3-C1FD09A69164

Q30493217-67AC2618-ECC5-4CA3-8877-375697D622F6

Q30493217-78618477-13EB-4F01-9565-A317DF477C0A

Q30493217-7EE832CD-B5D8-4693-9B40-EE1E174DA10B

Q30493217-81ED9B61-9893-4767-8DE5-69E988D18D4C

Q30493217-9391CF4C-E6C1-4216-8655-335A72B8E1AB

P304

Q30493217-AF8F94D6-0208-4194-A1A9-F06DBC0F8517

P31

Q30493217-9DE82E64-7DB1-4F82-BFD2-CE0EC43DAE7B

P356

Q30493217-C1EA34B6-E975-4FB7-8241-68D06AAA7085

P407

Q30493217-8C738A63-558D-4CE8-A060-C9DBB4845A59

P433

Q30493217-0CAA3A06-A302-4CC1-A3BD-4460C5A9CF10

P478

Q30493217-1287CCFC-C942-477F-B5A8-D9AB362B1187

P577

Q30493217-EF132FFA-879E-4272-912D-01E492861B08

P5875

Q30493217-D08D0494-97F6-4291-91EA-E67011EFA79F

P698

Q30493217-E972DC3C-C070-4D52-B715-ABABDBCAABF7

P921

Q30493217-101C45CC-6D6F-4AC1-8D9D-997A17D9937B

P932

Q30493217-36913DE9-F9C4-4AF1-9A8F-CB8188079E51

P356

0008-5472.CAN-09-0814

P1433

Cancer Research

P1476

A "vascular normalization inde ...... current glioblastoma patients.

@en

P2093

A Gregory Sorensen

http://www.w3.org/2001/XMLSchema#string

Dan G Duda

http://www.w3.org/2001/XMLSchema#string

Dominique Jennings

http://www.w3.org/2001/XMLSchema#string

Emmanuelle di Tomaso

http://www.w3.org/2001/XMLSchema#string

Johanna Lahdenranta

http://www.w3.org/2001/XMLSchema#string

Marek Ancukiewicz

http://www.w3.org/2001/XMLSchema#string

Meiyun Wang

http://www.w3.org/2001/XMLSchema#string

Patrick Y Wen

http://www.w3.org/2001/XMLSchema#string

Poe-Jou Chen

http://www.w3.org/2001/XMLSchema#string

Priscilla Yeo

http://www.w3.org/2001/XMLSchema#string

P2860

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Response criteria for glioma.

Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

Biomarkers of response and resistance to antiangiogenic therapy.

Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.

P304

5296-5300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-0814

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26314345

http://www.w3.org/2001/XMLSchema#string

P698

19549889

http://www.w3.org/2001/XMLSchema#string

P921

P932

2824172

http://www.w3.org/2001/XMLSchema#string